News | November 18, 2014

Mevion and Philips Collaborate to Offer Treatment Planning Solutions for Proton Pencil Beam Scanning

Companies to develop Pinnacle³ proton planning for the Mevion S250 proton therapy system featuring Hyperscan

Mevion Medical Systems, Inc. and Philips Radiation Oncology Systems are collaborating to combine the treatment planning capability of Philips’ Pinnacle³ radiation therapy planning system with the Mevion S250 solution with Hyperscan, Mevion’s new pencil beam scanning technology that is capable of scanning a tumor in seconds.

Pinnacle³ currently supports the Mevion S250, the world’s smallest proton therapy platform. The new collaboration will focus on enabling the Pinnacle³ system to also support Hyperscan.

Hyperscan is an advanced form of pencil-beam scanning and is only available on the Mevion S250. Since Pinnacle³ is already being used by certain Mevion S250 users, it’s only fitting that we work together to develop planning for Hyperscan,” said Joe Jachinowski, the president and chief executive officer of Mevion Medical Systems.

“We’re really pleased to be collaborating with Mevion as it introduces Hyperscan,” said Sue Wallace, PhD, general manager of Philips Radiation Oncology Systems. “At Philips, treatment planning is a critical element of informed therapy guidance, and the integration of Philips imaging and planning with therapy delivery systems is essential.”

The first site to use Pinnacle³ with the Mevion S250 is the UF Health Cancer Center at Orlando Health. Omar Zeidan, Ph.D., the center’s chief of proton therapy physics, noted, “The collaboration between Philips and Mevion will give world-class cancer centers like ours the ability to offer patients all the benefits of HYPERSCAN combined with the accuracy and reliability of Pinnacle³.”  Zeidan added, “This will help lead to well-planned and well-executed proton therapy sessions that accurately target tumors.”

Hyperscan’s patented technology, paired with the direct and efficient proton beam generation of the Mevion S250 platform, allows tumor volumes to be quickly scanned in a matter of seconds. This speed makes Hyperscan’s treatment delivery much less sensitive to patient and tumor motion. 

The Mevion S250’s revolutionary compact design removes the obstacles of size, complexity and cost that exist with conventional proton therapy systems without compromising beam quality or patient care. It was first installed at Barnes Jewish Hospital in St. Louis. Five other Mevion S250 installations are currently in process.

HYPERSCAN has not been cleared by the USFDA for clinical use.

For more information: www.mevion.com

Related Content

At the American Association of Physicists in Medicine (AAPM) 2019 meeting, new artificial intelligence (AI) software to assist with radiotherapy treatment planning systems was highlighted. The goal of the AI-based systems is to save staff time, while still allowing clinicians to do the final patient review. 
Feature | Treatment Planning | July 08, 2020 | By Melinda Taschetta-Millane
At the American Association of Physicists in Medicine (AAPM) 201
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
News | Proton Therapy | June 16, 2020
June 17, 2020 — RaySearch Laboratories AB launched the latest release of its widely adopted treatment planning system
Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Feature | Proton Therapy | May 27, 2020 | By Minesh Mehta, M.D.
Radiation therapy has advanced significantly in the last few decades as a result of a continued technological revolut
The global radiation therapy market is expected to reach $10.11 billion in 2024, witnessing growth at a CAGR of 3.38%, over the period 2020-2024.
News | Proton Therapy | May 20, 2020
May 20, 2020 — ResearchAndMarkets.com has released its latest report, the ...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
IBA ProteusOne proton therapy system
News | Proton Therapy | January 29, 2020
January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down